Related Experiment Video
Updated: Jan 9, 2026
07:45
Orthotopic Transplantation of Breast Tumors as Preclinical Models for Breast Cancer
Published on: May 18, 2020
6.9K
Prognostic Model Based on NAD+ Metabolism-Related Genes Predicts Breast Cancer Outcomes and Guides Immunotherapy
1Department of Tumor Radiotherapy, Four Provincial Border Central Hospital (Quzhou People's Hospital), Quzhou City, Zhejiang Province, China.
Cancer Investigation
|December 9, 2025
Summary
This study developed a new model using NAD+ metabolism-related genes to predict breast cancer (BCa) patient outcomes. The model identifies patients likely to respond to immunotherapy by analyzing immune cell infiltration.
Area of Science:
- Oncology
- Molecular Biology
- Immunology
Background:
- Breast cancer (BCa) is a prevalent malignancy in women.
- The prognostic significance of NAD+ metabolism-related genes (NMRGs) in BCa requires further elucidation.
Purpose of the Study:
- To identify core NMRGs and construct a prognostic risk model for BCa.
- To validate the model's prognostic capability and assess its correlation with immune infiltration.
- To investigate the expression of the identified risk gene POU3F2 in BCa.
Main Methods:
- Analysis of transcriptomic and clinical data from TCGA and GEO databases.
- Construction and validation of a multigene prognostic risk model using survival analysis.
- Assessment of immune cell infiltration and gene expression via qRT-PCR.
Main Results:
- Identified 14 NMRG-associated differentially expressed genes (DEGs).
- The prognostic model effectively stratified BCa patients into low- and high-risk groups.
- Low-risk group exhibited increased anti-tumor immune cell infiltration and higher immunophenoscore, suggesting potential immunotherapy benefits. POU3F2 was overexpressed in BCa cells.
Conclusions:
- A reliable BCa prognostic model based on NMRGs was developed and validated.
- The model demonstrates strong prognostic stratification ability and potential for guiding immunotherapy selection.
- This research offers a novel strategy for personalized immunotherapy in breast cancer patients.
